Your browser is no longer supported. Please, upgrade your browser.
Ovid Therapeutics Inc.
Index- P/E- EPS (ttm)-1.39 Insider Own31.04% Shs Outstand64.05M Perf Week-5.18%
Market Cap234.59M Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float41.28M Perf Month-5.69%
Income-81.00M PEG- EPS next Q1.68 Inst Own50.10% Short Float11.41% Perf Quarter9.09%
Sales12.60M P/S18.62 EPS this Y10.10% Inst Trans0.41% Short Ratio1.28 Perf Half Y-35.20%
Book/sh0.68 P/B5.12 EPS next Y-156.20% ROA-118.00% Target Price6.00 Perf Year-1.14%
Cash/sh1.07 P/C3.25 EPS next 5Y- ROE-171.30% 52W Range2.25 - 9.40 Perf YTD50.65%
Dividend- P/FCF- EPS past 5Y-21.00% ROI-186.80% 52W High-62.98% Beta1.82
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin- 52W Low54.67% ATR0.20
Employees67 Current Ratio3.40 Sales Q/Q- Oper. Margin- RSI (14)40.02 Volatility4.10% 5.50%
OptionableYes Debt/Eq0.00 EPS Q/Q0.20% Profit Margin- Rel Volume0.09 Prev Close3.46
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.69M Price3.48
Recom2.10 SMA20-6.17% SMA50-8.97% SMA200-24.31% Volume335,713 Change0.58%
Apr-20-21Downgrade Cantor Fitzgerald Buy → Neutral $4
Mar-03-21Downgrade RBC Capital Mkts Outperform → Sector Perform $5
Dec-02-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-02-20Downgrade Citigroup Buy → Neutral $10 → $4
Sep-04-19Initiated RBC Capital Mkts Outperform $12
Apr-20-18Initiated Ladenburg Thalmann Buy $27
May-07-21 08:42AM  
Apr-30-21 11:37AM  
Apr-20-21 08:00AM  
Apr-19-21 09:16AM  
Mar-30-21 08:00AM  
Mar-20-21 04:51AM  
Mar-16-21 08:39AM  
Mar-15-21 08:00AM  
Mar-10-21 03:44AM  
Mar-03-21 07:46AM  
Jan-15-21 02:22AM  
Dec-16-20 07:00AM  
Dec-02-20 11:38AM  
Dec-01-20 04:52PM  
Nov-25-20 08:51AM  
Nov-23-20 04:01PM  
Nov-16-20 06:07AM  
Nov-12-20 04:10PM  
Oct-14-20 07:00AM  
Oct-12-20 07:00AM  
Oct-05-20 05:30AM  
Sep-30-20 08:00AM  
Sep-11-20 08:00AM  
Aug-25-20 07:50AM  
Aug-10-20 08:00AM  
Aug-05-20 09:00AM  
Jul-25-20 09:10AM  
Jul-23-20 07:00AM  
Jul-14-20 06:35AM  
Jul-13-20 09:00AM  
Jul-08-20 09:20PM  
Jun-29-20 08:00AM  
Jun-25-20 08:58AM  
Jun-22-20 09:02AM  
Jun-19-20 08:00AM  
Jun-11-20 08:00AM  
Jun-08-20 08:00AM  
Jun-04-20 08:00AM  
May-12-20 08:00AM  
May-07-20 08:00AM  
Apr-22-20 11:50AM  
Apr-09-20 10:08AM  
Mar-30-20 08:00AM  
Mar-11-20 08:00AM  
Mar-05-20 04:06PM  
Mar-02-20 08:00AM  
Feb-25-20 08:00AM  
Jan-23-20 06:00PM  
Jan-21-20 05:09PM  
Jan-10-20 11:43AM  
Jan-07-20 08:00AM  
Dec-19-19 10:20PM  
Dec-06-19 01:13PM  
Nov-26-19 08:00AM  
Nov-18-19 04:05PM  
Nov-08-19 08:00AM  
Nov-01-19 08:00AM  
Oct-16-19 07:01AM  
Oct-12-19 09:25AM  
Oct-11-19 08:23PM  
Oct-04-19 08:30AM  
Oct-03-19 04:01PM  
Sep-24-19 09:27AM  
Sep-23-19 07:00AM  
Sep-20-19 12:25PM  
Sep-12-19 08:00AM  
Sep-09-19 08:00AM  
Sep-03-19 08:00AM  
Aug-07-19 04:05PM  
Jul-09-19 03:27PM  
Jul-02-19 08:00AM  
Jun-27-19 08:00AM  
Jun-18-19 08:00AM  
May-23-19 04:50PM  
May-07-19 08:00AM  
May-06-19 04:56PM  
Apr-27-19 09:43AM  
Apr-18-19 08:00AM  
Mar-28-19 08:00AM  
Mar-21-19 08:00AM  
Mar-07-19 04:05PM  
Mar-04-19 08:00AM  
Feb-20-19 04:01PM  
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEVIN JEREMY MCEOAug 28Buy5.848,48849,5705,792,530Sep 01 09:34 PM